-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, there have been frequent reports of good news from Huahai Pharmaceutical
.
Following the approval of the ANDA for nebivolol tablets, the ANDA for apixaban tablets was also provisionally approved
.
Up to now, the company has invested about 7.
78 million yuan in research and development expenses in the apixaban tablet project
.
According to Minet.
com, global sales of apixaban in 2021 will exceed $10 billion
.
Basic drug information Apixaban tablets are mainly used to reduce the risk of stroke and systemic embolism
.
It was developed by Bristol-Myers Squibb and launched in the United States in 2013.
Because the drug is still in the patent protection period, currently only the original research product is on the market in the United States
.
According to data from Minet.
com, the global sales of apixaban in 2021 will reach a new high, exceeding US$10 billion
.
Huahai Pharmaceutical stated that the temporary approval number of apixaban tablets obtained by the US FDA will help the company to strengthen the product supply chain, enrich the product echelon, enhance the market competitiveness of the company's products, and have a positive impact on the company's expansion of the US market
.
It is worth mentioning that the provisional approval number of apixaban tablets obtained by the US FDA indicates that the product has passed all the review requirements for generic drugs, but the product needs to be obtained after the patent right expires and is finally approved by the FDA.
Eligibility for sale in the US market
.
Up to now, the company has invested about 7.
78 million yuan in research and development expenses in the apixaban tablet project
.
Since April, there have been frequent reports of good news from Huahai Pharmaceutical
.
The ANDAs of Nebivolol Tablets, Levetiracetam Injection, and Febuxostat Tablets have been approved, and the ANDAs of Linagliptin Metformin Tablets and Apixaban Tablets have been provisionally approved; Levetiracetam for Injection The concentrated solution was approved for marketing as a generic category 4, which is deemed to be over-evaluated; HHT120 capsules, which are intended to be used for the prevention of venous thromboembolism after major orthopaedic surgery, were approved for clinical use
.
Source: Company announcement, Minet database
.
Following the approval of the ANDA for nebivolol tablets, the ANDA for apixaban tablets was also provisionally approved
.
Up to now, the company has invested about 7.
78 million yuan in research and development expenses in the apixaban tablet project
.
According to Minet.
com, global sales of apixaban in 2021 will exceed $10 billion
.
Basic drug information Apixaban tablets are mainly used to reduce the risk of stroke and systemic embolism
.
It was developed by Bristol-Myers Squibb and launched in the United States in 2013.
Because the drug is still in the patent protection period, currently only the original research product is on the market in the United States
.
According to data from Minet.
com, the global sales of apixaban in 2021 will reach a new high, exceeding US$10 billion
.
Huahai Pharmaceutical stated that the temporary approval number of apixaban tablets obtained by the US FDA will help the company to strengthen the product supply chain, enrich the product echelon, enhance the market competitiveness of the company's products, and have a positive impact on the company's expansion of the US market
.
It is worth mentioning that the provisional approval number of apixaban tablets obtained by the US FDA indicates that the product has passed all the review requirements for generic drugs, but the product needs to be obtained after the patent right expires and is finally approved by the FDA.
Eligibility for sale in the US market
.
Up to now, the company has invested about 7.
78 million yuan in research and development expenses in the apixaban tablet project
.
Since April, there have been frequent reports of good news from Huahai Pharmaceutical
.
The ANDAs of Nebivolol Tablets, Levetiracetam Injection, and Febuxostat Tablets have been approved, and the ANDAs of Linagliptin Metformin Tablets and Apixaban Tablets have been provisionally approved; Levetiracetam for Injection The concentrated solution was approved for marketing as a generic category 4, which is deemed to be over-evaluated; HHT120 capsules, which are intended to be used for the prevention of venous thromboembolism after major orthopaedic surgery, were approved for clinical use
.
Source: Company announcement, Minet database
